Azitra is trading 13.4% down at $0.97, with no confirmed company-specific announcement explaining the October 28 move.
- An October 26 release reported positive ex vivo ATR-COSF results and anticipated initial human-study data by year-end; that earlier news does not establish the cause of the decline.
- Biotech shares are reported higher, so sector strength does not explain Azitra’s opposite-direction move.